Related Experiment Videos
[Chemotherapy in elderly patients with hematological malignancies]
1Hamamatsu University, Oncology Center, Hamamatsu, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 15, 2011
Summary
Elderly patients with acute myeloid leukemia and lymphoma often need tailored chemotherapy. Chronological age is a poor predictor of risk; comorbidity and specific age thresholds guide treatment decisions for better outcomes.
Area of Science:
- Hematology
- Oncology
- Geriatric Medicine
Context:
- Acute myeloid leukemia (AML) and lymphoma disproportionately affect individuals over 60.
- Traditional risk stratification using chronological age in chemotherapy is often unreliable for elderly cancer patients.
- Comorbidity assessment is crucial for determining appropriate treatment intensity.
Purpose:
- To evaluate the limitations of chronological age in predicting chemotherapy risks for elderly patients with AML and lymphoma.
- To propose age-and-comorbidity-based treatment strategies for older adults with these hematologic malignancies.
- To highlight the potential role of molecular targeted therapy in this demographic.
Summary:
- Approximately 50% of patients diagnosed with AML or lymphoma are over 60 years old.
- Treatment decisions should consider comorbidity and specific age cutoffs (e.g., >75 years) rather than solely chronological age.
- Reduced chemotherapy doses, palliative care, or molecular targeted therapies are recommended for elderly patients with complex conditions or advanced age.
Impact:
- Improved risk stratification for chemotherapy in elderly cancer patients.
- Personalized treatment approaches for acute myeloid leukemia and lymphoma, enhancing patient tolerance and efficacy.
- Guidelines for managing geriatric patients with hematologic malignancies, potentially improving survival and quality of life.
Related Concept Videos
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...